

DUPONT™ TYVEK® 1073B AND TYVEK® 1059B TRANSITION PROTOCOL TIMELINE

Prior to 2010	Phase 1 1Q 2010 to 2Q 2011	Phase 2 3Q 2011 to 4Q 2011	Phase 3 1Q 2012 to 2Q 2012	Phase 4 3Q 2012 to 4Q 2012	Phase 5 1Q 2013 to 2Q 2014	Phase 6 3Q 2014 to 3Q 2015	Phase 7 4Q 2015 to 2Q 2018
Extensive preliminary testing of developmental samples; results promising	<p>Explore product and process fundamentals</p> <hr/> <p>Design of Experiments (“DOE”) runs at Richmond, Va., and Luxembourg sites</p> <hr/> <p>U.S. FDA approval of transition protocol</p>	<p>Customer testing and evaluation of prototypic DOE materials</p> <hr/> <p>Announcement of transition protocol</p> <hr/> <p>Acceptance of transition protocol by Japanese Ministry of Health, Labour and Welfare, select European Notified Bodies and Chinese SFDA</p> <hr/> <p>Selection of SPMs and MDMs to participate in protocol testing</p> <hr/> <p>Selection of third-party laboratory for protocol testing</p> <hr/> <p>Verification/ optimization runs at Richmond, Va., site</p> <hr/> <p>Verification/ optimization runs at Luxembourg site</p>	<p>Customer testing and evaluation of prototypic verification/ optimization materials</p> <hr/> <p>Sterilization and aging studies on prototypic verification/ optimization materials</p> <hr/> <p>Validation runs at Richmond, Va., site</p> <hr/> <p>Validation runs at Luxembourg site</p>	<p>Protocol package creation and sterilization</p> <hr/> <p>Initiate protocol data generation and collection</p>	<p>Complete Year 1 data generation and collection (including accelerated aging)</p> <hr/> <p>Year 1 data analysis and report generation</p> <hr/> <p>Submit report to the U.S. FDA</p> <hr/> <p>Expect U.S. FDA to affirm functional equivalence</p>	<p>Transition period for SPMs and MDMs to begin using Tyvek® 1073B and Tyvek® 1059B manufactured on the newer equipment</p> <hr/> <p>Complete Year 2.5 data generation and collection</p> <hr/> <p>Year 2.5 data analysis and report generation</p> <hr/> <p>Submit additional report to the U.S. FDA</p>	<p>Complete Year 5 data generation and collection</p> <hr/> <p>Year 5 data analysis and report generation</p> <hr/> <p>Submit additional report to the U.S. FDA</p>